The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis

INTRODUCTION: RA-BE-REAL has the overall aim of defining a profile of patients with rheumatoid arthritis (RA) starting baricitinib or any other targeted synthetic (ts) or any biologic (b) disease-modifying antirheumatic drug (DMARD) for the first time, and the primary objective of estimating time un...

Descripción completa

Detalles Bibliográficos
Autores principales: Alten, Rieke, Burmester, Gerd R., Matucci-Cerinic, Marco, Salmon, Jean-Hugues, Lopez-Romero, Pedro, Fakhouri, Walid, de la Torre, Inmaculada, Zaremba-Pechmann, Liliana, Holzkämper, Thorsten, Fautrel, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557042/
https://www.ncbi.nlm.nih.gov/pubmed/36227530
http://dx.doi.org/10.1007/s40744-022-00500-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557042/
https://www.ncbi.nlm.nih.gov/pubmed/36227530
http://dx.doi.org/10.1007/s40744-022-00500-6

Ejemplares similares